Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution

• Published in: Frontiers in oncology Vol. 13; p. 1150098
• Main Authors: Liu, Jun, Ji, Yaxin, Weng, Xiaodan, Shao, Wei, Zhao, Jiaping, Chen, Hanlin, Shen, Lu, Wang, Fufeng, Meng, Qi, Wu, Xue, Wang, Xiaonan, Ou, Qiuxiang, Ke, Honggang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 23.06.2023
• Subjects: biomarkers; early-stage lung adenocarcinoma; immune microenvironment; Oncology; RNA-sequencing; tumor evolution; RNA-sequencing; tumor evolution; early-stage lung adenocarcinoma; immune microenvironment; biomarkers
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1150098

Lung cancer is the deadliest and most diagnosed type of cancer worldwide. The 5-year survival rate of lung adenocarcinoma (LUAD) dropped significantly when tumor stages advanced. Patients who received surgically resecting at the pre-invasive stage had a 5-year survival rate of nearly 100%. However, the study on the differences in gene expression profiles and immune microenvironment among pre-invasive LUAD patients is still lacking. In this study, the gene expression profiles of three pre-invasive LUAD stages were compared using the RNA-sequencing data of 10 adenocarcinoma in situ (AIS) samples, 12 minimally invasive adenocarcinoma (MIA) samples, and 10 invasive adenocarcinoma (IAC) samples. The high expression levels of PTGFRN (Hazard Ratio [HR] = 1.45; 95% Confidence Interval [CI]: 1.08-1.94; log-rank P = 0.013) and SPP1 (HR = 1.44; 95% CI: 1.07-1.93; log-rank P = 0.015) were identified to be associated with LUAD prognosis. Moreover, the early LUAD invasion was accompanied by the enhancement of antigen presentation ability, reflected by the increase of myeloid dendritic cells infiltration rate (Cuzick test P < 0.01) and the upregulation of seven important genes participating in the antigen presentation, including HLA-A (Cuzick test P = 0.03), MICA (Cuzick test P = 0.01), MICB (Cuzick test P = 0.01), HLA-DPA1 (Cuzick test P = 0.04), HLA-DQA2 (Cuzick test P < 0.01), HLA-DQB1 (Cuzick test P = 0.03), and HLA-DQB2 (Cuzick test P < 0.01). However, the tumor-killing ability of the immune system was inhibited during this process, as there were no rising cytotoxic T cell activity (Cuzick test P = 0.20) and no increasing expression in genes encoding cytotoxic proteins. In all, our research elucidated the changes in the immune microenvironment during early-stage LUAD evolution and may provide a theoretical basis for developing novel early-stage lung cancer therapeutic targets.